Granahan Investment Management LLC Buys 496,482 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Granahan Investment Management LLC lifted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 43.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,636,381 shares of the company’s stock after purchasing an additional 496,482 shares during the quarter. Granahan Investment Management LLC owned about 0.80% of Taysha Gene Therapies worth $2,831,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. bought a new position in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $8,650,000. Bank of America Corp DE lifted its position in Taysha Gene Therapies by 1,178.9% during the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock valued at $2,959,000 after purchasing an additional 1,576,568 shares during the last quarter. Norges Bank purchased a new position in shares of Taysha Gene Therapies in the 4th quarter worth $2,528,000. Avoro Capital Advisors LLC increased its holdings in shares of Taysha Gene Therapies by 7.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock worth $34,600,000 after buying an additional 1,349,999 shares during the last quarter. Finally, B Group Inc. bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth about $1,670,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Price Performance

Shares of TSHA stock opened at $2.13 on Friday. The company has a market capitalization of $436.77 million, a P/E ratio of 3.38 and a beta of 0.90. The company’s 50-day simple moving average is $1.65 and its two-hundred day simple moving average is $1.81. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The business had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. As a group, equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on TSHA shares. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.